Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06716658RecruitingPhase 2
New targeted drug for certain T/NK-cell lymphomas
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06738368RecruitingPhase 2
Chemo plus asparaginase for new ALL in adults
This trial tests a combination of chemotherapy drugs (DA-EPOCH) with or without rituximab, plus a special form of the enzyme asparaginase (JZP458), for adults with newly diagnosed B-ALL or T-ALL. It aims to offer an effective option for those who cannot have standard pediatric-style treatment, such as older adults.
Seattle, WashingtonAges 18 years+ - NCT06756152RecruitingPhase 2/Phase 3
Preventing GVHD after transplant for blood cancers in children and young adults
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
MoscowAges 1 day–21 years - NCT06777979RecruitingPhase 1
CAR T cell therapy for children with hard-to-treat leukemia
This trial tests a special kind of immune cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It is for children and teens whose leukemia has come back multiple times or has not responded to standard treatment.
Memphis, TennesseeAges Up to 21 years - NCT06810583RecruitingPhase 1
Dalbavancin to prevent infections in kids with leukemia
This trial tests if an antibiotic called dalbavancin can help prevent serious bacterial infections in children and young adults with high-risk leukemia whose immune systems are weakened by treatment.
Memphis, TennesseeAges Up to 25 years - NCT06839053RecruitingPhase 2
Study of sonrotoclax, rituximab, and zanubrutinib for CLL, SLL, and MCL
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
Seattle, WashingtonAges 18 years+ - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT06869265RecruitingPhase 2
Thiotepa added to standard chemo before a stem cell transplant for older adults with high-risk AML
This trial tests whether adding a drug called thiotepa to the usual chemotherapy (busulfan and fludarabine) before a half-matched stem cell transplant can safely and effectively treat older adults (55–70) with high-risk AML.
Beijing, Beijing MunicipalityAges 55–70 - NCT06965114RecruitingPhase 1/Phase 2
Testing tovorafenib plus rituximab for hairy cell leukemia
This trial tests a new drug combination (tovorafenib and rituximab) for people with hairy cell leukemia (HCL) whose cancer has a specific genetic change called BRAF V600E. It looks at safety and how well the drugs work, both for people who have had treatment before and for those who have not.
Bethesda, MarylandAges 18 years+ - NCT06994676RecruitingPhase 1
Study of CBX-250 for advanced myeloid leukemias
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
Duarte, CaliforniaAges 12 years+ - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+ - NCT07205523Recruiting
High-altitude blood study for stem cell transplant patients
This study observes how blood and stem cell transplants work for patients with blood diseases at high altitude. It aims to learn more to help future patients.
Xining, QinghaiAges Any age - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT07292272Recruiting
Slowing Aging in Blood Cancer Survivors
This study tests a program to help people who have survived a blood cancer stay healthier as they age. It involves exercise and check-ups to see if we can slow down some effects of aging.
Omaha, NebraskaAges 50 years+ - NCT04411043Recruiting
Study of T prolymphocytic leukemia patients
This is an observational study for adults diagnosed with T prolymphocytic leukemia. It aims to learn more about the disease and your care over time, which may help improve treatment planning in the future.
Le MansAges 18 years+ - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT01890486Recruiting
Collecting information from people having a stem cell transplant
This study aims to collect, store, and share data from patients who are receiving standard intensive treatment and a stem cell transplant from either their own cells or a donor. It may help improve how future patients are treated by building a reliable record of outcomes and care patterns.
Winston-Salem, North CarolinaAges 18–120 - NCT01746836RecruitingPhase 2
Ponatinib for CML that didn’t respond to prior pills
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
Houston, TexasAges 18 years+ - NCT02390635RecruitingPhase 1
Testing PET/MRI scans to find leukemia outside the bone marrow
This Phase 1 study uses special whole-body imaging scans (PET with CT, plus MRI) to look for signs of acute myeloid leukemia outside the bone marrow. It may help doctors better see where leukemia is and guide future care.
Houston, TexasAges 18 years+ - NCT02760238Recruiting
Myeloproliferative Neoplasms patient registry study
This is a research registry for people who have certain blood cancers called myeloproliferative neoplasms (MPNs). It helps researchers learn about the disease over time and may help future studies find and compare patients.
Toronto, OntarioAges Any age - NCT02863692Recruiting
Registry study for chronic lymphocytic leukemia patients
This study is a registry that collects information about people with certain types of leukemia. It may help researchers understand the disease course and how patients are treated, including people who are newly diagnosed, currently treated, referred for transplant, or have relapsed.
Dresden, SaxonyAges 18 years+ - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07537738Recruiting
Blood test to predict outcomes in MLL acute myeloid leukemia
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
BeijingAges 6–60 - NCT07094750Recruiting
Comparing treatment intensities for less fit adults with AML
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
Seattle, WashingtonAges 18 years+
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,319 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.